Switzerland

All.Can around the world

All.Can Switzerland

Cancer care in Switzerland

Switzerland is known for having one of the best healthcare systems in the world. The decentralised structure favours an almost unconstrained choice of providers and a high availability and accessibility of healthcare services. However, this comes at a significant cost: health expenditure in Switzerland is higher than in most Organisation for Economic Co-operation and Development (OECD) countries. This is why international organisations like the World Health Organization and OECD have pointed out that Switzerland’s main challenges lie in becoming more cost-effective.1 Indeed, with the second highest healthcare spending in the world2 and an above-average investment in cancer care of more than 6%,3 Switzerland produces lower health outcomes per money spent compared with other countries.4

Every year, more than 40,000 Swiss citizens are diagnosed with cancer.5 While incidence rates for cancer have remained constant since 1980, mortality rates have dropped by more than 30%. This achievement was possible thanks to medical advances in diagnostic technology, medicines and care.6 Nonetheless, the diagnosis for people with cancer still comes with a high burden for patients as well as their environment. There are countless opportunities across Switzerland to make cancer care more efficient and more sustainable. In particular, cancer care should become more patient-centred, focusing on patient needs and patient-reported outcomes. This is what All.Can Switzerland intends to do.

All.Can Switzerland initiative

All.Can Switzerland’s vision is to define solutions for sustainable cancer care, with a strong focus on improving patient outcomes. All.Can Switzerland wants to achieve this through an open dialogue and a broad collaboration with all interested stakeholders sharing the same vision.

All.Can Switzerland launched in early 2018 with a handful of interested stakeholders. Throughout the year, its first projects were initiated. In November, the board of All.Can Switzerland met for the first time to discuss the strategy, organisational set-up and the governance of the organisation. The steering committee is currently working on the finalisation of these governing documents, as well as a project description. The documents shall be published on this page in the course of 2019. Furthermore, an official launch event will take place towards the end of 2019.

All.Can Switzerland is a group of excited stakeholders who want to achieve meaningful change in the field of cancer in Switzerland. We are actively looking for interested parties to join us. Interested in All.Can Switzerland? Please get in touch with us: switzerland@all-can.org

References:

1. OECD. 2011. OECD Reviews of Health Systems – Switzerland, p. 9. http://www.oecd.org/switzerland/oecdreviewsofhealthsystems-switzerland.htm [accessed 18 May 2018]
2. OECD. 2018. Health spending. https://data.oecd.org/chart/5b8O [accessed 18 May 2018]
3. Wieser et al. 2014. Die Kosten der nichtübertragbaren Krankheiten in der Schweiz, Schlussbericht, p. 52. http://bit.ly/zhaw14 [accessed 6 August 2018]
4. OECD. 2018. http://stats.oecd.org/ [accessed 18 May 2018]
5. Heusser et al. 2017. Krebs in der Schweiz, Zahlen Weiterentwicklung der Krebsregistrierung und Folgen, in: Onkologe, 23:588-596. doi: 10.1007/s00761-017-0252-4
6. Federal Office of Statistics/NICER. 2017. Schweizer Krebsbericht 2015. http://bit.ly/Krebsbericht [accessed 6 August 2018]

Disclaimer:

The All.Can initiative is made up of leading representatives of patient organisations, policymakers, healthcare professionals, science and industry. All the publications produced under the initiative reflect the consensus of All.Can members who have full editorial control. The All.Can initiative in Switzerland is supported (financially and/or in kind) by Amgen, Bristol-Myers Squibb, MSD, mysurvivalstory.com, Lucerne University of Applied Sciences and Arts, and University of Zurich.

All.Can is a trademark of The Health Policy Partnership Ltd.

Board

Professor Dr Brigitte Tag

Professor Dr Brigitte Tag

Dean, Faculty of Law, Chair for Criminal and Medical Law, University of Zurich

Michelle Calope

Michelle Calope

General Manager, Bristol-Myers Squibb

Henrik Asmussen

Henrik Asmussen

General Manager, Amgen

Thomas Lang

Thomas Lang

General Manager, MSD

Oliver Kessler

Oliver Kessler

Lucerne University of Applied Sciences and Arts, Competence Center for Public and Nonprofit Management

Martin Inderbitzin

Martin Inderbitzin

My Survival Story Foundation

Steering Committee

Daniel Widrig

Daniel Widrig

Bristol-Myers Squibb; Co-chair of steering committee

Isabel Baur

Isabel Baur

University of Zurich, Competence Center for Medical Ethics and Law Helvetiae; Co-chair of steering committee

Dominic Zahn

Dominic Zahn

Value, Access & Policy Manager, Amgen

Damiano Urbinello

Damiano Urbinello

MSD

Nicole Schlumberger

Nicole Schlumberger

Bristol-Myers Squibb

Resources

Interview with Isabel Baur

Isabel Baur, University of Zurich, Competence Center for Medical Ethics and Law Helvetiae, talks about the ‘fresh ideas for cancer care’ project, which unites PhD students with stakeholders from various sectors to develop innovations in cancer care.

English version:

German version:

Interview with Oliver Kessler

Oliver Kessler, Lucerne University of Applied Sciences and Arts, Competence Center for Public and Nonprofit Management, talks about the All.Can Switzerland project focusing on optimising cancer care in central Switzerland.

English version:

German version: